Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Asgard Therapeutics AB has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is being handled by a distinct examiner and is situated in a single art unit. This indicates a centralized review process for the company's current patent applications. Centralization can help maintain a consistent prosecution strategy for the company's biotechnology assets.
MONTANARI, DAVID A is the busiest examiner for the portfolio, managing 1 pending office action. This represents the totality of the 1 pending office action for the company. The prosecution of this biotechnology asset is subject to the specific standards of this single examiner and art unit. Understanding the examiner's technical background in the Biotechnology & Pharmaceuticals area will be critical for navigating the current pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17778901 | COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS TYPE 2 COMPETENT FOR ANTIGEN PRESENTATION, METHODS AND USES THEREOF | MONTANARI, DAVID A | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17778901 | COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS TYPE 2 COMPETENT FOR ANTIGEN PRESENTATION, METHODS AND USES THEREOF | MONTANARI, DAVID A | 1632 | §103 | Final Rejection | — | Pending | May 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsgard Therapeutics AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David A Montanari has the most, with 1 of Asgard Therapeutics AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
